The subject invention relates to improved tocopheryl quinone derivatives and tocopherol derivatives having improved pharmacokinetics in vivo that can, in some embodiments, be useful in the treatment of Lysosomal Storage Disorders, restoration of normal mitochondrial ATP production, modulation of intracellular calcium ion concentration and other treatments or therapies. The tocopheryl quinone derivatives and tocopherol derivatives have side chains that have terminally halogenated carbon atoms.

The subject invention relates to improved tocopheryl quinone derivatives and tocopherol derivatives having improved pharmacokinetics in vivo that can, in some embodiments, be useful in the treatment of Lysosomal Storage Disorders, restoration of normal mitochondrial ATP production, modulation of intracellular calcium ion concentration and other treatments or therapies. The tocopheryl quinone derivatives and tocopherol derivatives have side chains that have terminally halogenated carbon atoms.

The present description discloses a preferred solution for controlling oxidation of reduced coenzyme Q10 (QH) without any need for formulation of QH. One or more embodiments of the present invention relate to a method for storing QH, including storing a composition containing solid QH and water, a method for controlling oxidation of QH, including storing a composition containing solid QH and water, and a liquid composition containing solid QH in water. The solid QH is preferably one or more selected from the group consisting of a Form I crystal, a Form II crystal, an amorphous solid, and a co-crystal composed of QH and one or more other compounds.